CN104490982B - A kind of eucommia bark depressor slow releasing preparation and preparation method thereof - Google Patents
A kind of eucommia bark depressor slow releasing preparation and preparation method thereof Download PDFInfo
- Publication number
- CN104490982B CN104490982B CN201410706676.2A CN201410706676A CN104490982B CN 104490982 B CN104490982 B CN 104490982B CN 201410706676 A CN201410706676 A CN 201410706676A CN 104490982 B CN104490982 B CN 104490982B
- Authority
- CN
- China
- Prior art keywords
- parts
- slow releasing
- releasing preparation
- eucommia bark
- cortex eucommiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The present invention relates to a kind of eucommia bark depressor slow releasing preparation and preparation method thereof, belong to field of traditional Chinese.It is made up of Cortex Eucommiae extract and adjuvant.Described adjuvant to be selected from hypromellose, polyacrylic resin, ethyl cellulose, cellulose acetate, chitosan, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, lactose, calcium hydrogen phosphate, starch, mannitol, sorbitol, Polyethylene Glycol, glucose, Pulvis Talci, micropowder silica gel, calcium bicarbonate or magnesium stearate one or more.In the present invention further embodiment, described adjuvant is preferably polyacrylic resin, chitosan, cellulose acetate, lactose, mannitol and magnesium stearate.The present invention, in conjunction with the feature of Cortex Eucommiae extract, select suitable adjuvant to be prepared into skeleton gel rubber sustained-release sheet, not only good stability, and slow release effect is excellent.
Description
Technical field
The present invention relates to a kind of eucommia bark depressor slow releasing preparation and preparation method thereof, belong to field of traditional Chinese.
Background technology
Hypertension is modal chronic disease, and be also the topmost risk factor of cardiovascular and cerebrovascular disease, apoplexy, myocardial infarction, heart failure and chronic kidney disease are its major complications.Both domestic and externally facts have proved, hypertension is can the disease of prevention and corntrol, reduces the blood pressure level of hyperpietic, can obviously reduce apoplexy and the events of heart attack, significantly improve the life quality of patient, effectively reduce Disease Spectrum.The blood pressure level of hypertensive hazardness and patient mutually outside the Pass, also depend on the situation of other diseases of other cardiovascular risk factors simultaneous, target organ damage and merging.Therefore in hypertensive definition and classification, hypertensive diagnostic criteria is fixed on systolic pressure >110mmH and (or) diastolic pressure >90mmHg, be divided into normally according to blood pressure level, outside High-normal blood pressure and 1,2,3 grade of hypertension, also carry out risk stratification according to risk factor, target organ damage and the other diseases that merges simultaneously simultaneously.
Treating hypertensive main purpose is reduce cardiovascular morbidity and dead total danger to greatest extent, therefore require that doctor is treating hypertensive while, intervene the clinical disease that all reversibility cardiovascular risk factors of patient, target organ damage and merging exist.Be below 140/90mmHg for general hyperpietic's blood pressure lowering target, for the high risk patient such as complication with diabetes or nephropathy, blood pressure should take the circumstances into consideration to be down to more low-level in the tolerant situation of patient.
The Cortex Eucommiae begin be loaded in Shennong's Herbal, clinical practice has the history of more than one thousand years, because of its invigorating the liver and kidney, bone and muscle strengthening, admittedly rushes effect that is antiabortive, blood pressure lowering, pay attention to by medical scholar.At all times in TCM Literature, have hundreds of prescription to record, inside and outside, woman, youngster, bone, Shang Ge section have.The Cortex Eucommiae clinically, is mainly used in treatment deficiency of the liver and kindey, asthenia of essence and blood, the debility of CHONG and REN meridians and hypertension.Modem medical practices proves, the Cortex Eucommiae has significant curative effect to Zhejiang, foot and knee flaccidity, hypertension, frequent micturition, the frequent fetal movement etc. of suffering from a deficiency of the kidney disease more than wet, the urine of itching under waist knee joint ache, the moon.On market, the antihypertensive effect of existing eucommia bark depressor preparation (comprising folk prescription and compound preparation) is better, good effect is achieved through clinical practice, but its preparation mostly is the common formulations such as tablet, capsule, granule, pill or oral liquid, wherein the concentration of contained drug active component and purity lower, dose is large, is unfavorable for giving full play to of drug effect.
Patent CN200610110223 discloses a kind of Cortex Eucommiae compound slow release preparation, it adopts PLA to be timbering material, but its complicated process of preparation, and it uses in Shi Xu patients with implantation tissue cavity, easily cause patient uncomfortable, in addition, Chinese medicine extract complicated component, therefore implant stability and histocompatibility poor.
Summary of the invention
An object of the present invention is to provide a kind of eucommia bark depressor slow releasing preparation, it is directly oral, good stability, and patient only needs to take medicine once every day, and blood drug level and therapeutic effect are stablized.
Technical scheme of the present invention is as follows:
A kind of eucommia bark depressor slow releasing preparation, it is made up of Cortex Eucommiae extract and adjuvant.
Described adjuvant to be selected from hypromellose, polyacrylic resin, ethyl cellulose, cellulose acetate, chitosan, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, lactose, calcium hydrogen phosphate, starch, mannitol, sorbitol, Polyethylene Glycol, glucose, Pulvis Talci, micropowder silica gel, calcium bicarbonate or magnesium stearate one or more.
In the present invention further embodiment, described adjuvant is preferably polyacrylic resin, chitosan, cellulose acetate, lactose, mannitol and magnesium stearate.Described polyacrylic resin can select No. II, domestic polyacrylic resin or EudragitL100-55 (German rohm).
In one embodiment of the invention, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
In one embodiment of the invention, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
In another embodiment of the invention, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
In a preferred embodiment of the present invention, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
Another object of the present invention is to provide a kind of method preparing above-mentioned eucommia bark depressor slow releasing preparation, and concrete steps are as follows:
(1) Cortex Eucommiae extract, polyacrylic resin, chitosan, cellulose acetate, lactose and mannitol are uniformly mixed 15 minutes in high-speed mixer, obtain uniformed powder;
(2) in powder body, add appropriate 30% ethanol to granulate, vacuum drying makes water content lower than 5%, crosses 16 mesh sieves, and add magnesium stearate mixing, method tabletting, to obtain final product routinely.
In the present invention, Cortex Eucommiae extract source is not limit, and it can be the extract of Folium Eucommiae, root, stem or flower, also can their mixture, and said extracted thing is all adopted this area routine techniques means preparation or directly obtained by commercial means.
Usually containing lignin, iridoids, Phenylpropanoid Glycosides class, terpenoid and polysaccharide compound in traditional Cortex Eucommiae extract, composition is comparatively complicated, the problem such as less stable and blood drug level instability is easily there is after being prepared into slow releasing preparation, the present invention is in conjunction with the feature of Cortex Eucommiae extract, suitable adjuvant is selected to be prepared into skeleton gel rubber sustained-release sheet, not only good stability, and slow release effect is excellent.
Accompanying drawing explanation
Fig. 1: the plasma concentration curve after slow releasing tablet prepared by Oral Administration in Rats embodiment 1-2
Detailed description of the invention
The present invention is illustrated below in conjunction with accompanying drawing and further detailed description in detail.It is pointed out that following explanation is only illustrating the technical scheme that application claims is protected, any restriction not to these technical schemes.The content that protection scope of the present invention is recorded with appended claims is as the criterion.
Embodiment 1
(1) 300g Cortex Eucommiae extract, 150g polyacrylic resin, 100g chitosan, 50g cellulose acetate, 150g lactose and 100g mannitol are uniformly mixed 15 minutes in high-speed mixer, obtain uniformed powder;
(2) in powder body, add appropriate 30% ethanol to granulate, vacuum drying makes water content lower than 5%, crosses 16 mesh sieves, and add the mixing of 2g magnesium stearate, method tabletting, to obtain final product routinely.The heavy 300mg of sheet, suppresses 290.
Embodiment 2
(1) 300g Cortex Eucommiae extract, 100g polyacrylic resin, 150g chitosan, 100g cellulose acetate, 100g lactose and 100g mannitol are uniformly mixed 15 minutes in high-speed mixer, obtain uniformed powder;
(2) in powder body, add appropriate 30% ethanol to granulate, vacuum drying makes water content lower than 5%, crosses 16 mesh sieves, and add the mixing of 2g magnesium stearate, method tabletting, to obtain final product routinely.The heavy 300mg of sheet, suppresses 290.
The Cortex Eucommiae extract adopted in embodiment 1 and 2 is the water extract (weight ratio of root, stem and leaf is 1:1:1) of Cortex Eucommiae root, stem and leaf, preparation method adopts more traditional aqueous extraction-alcohol precipitation technology, 8 times of water gaging reflux, extract, 3 times, each 1h, merging filtrate, concentrated, adjust ethanol content to 90%, spend the night, filter rear concentrate drying and get final product.
Embodiment 3
Investigate correlated samples stability according to the stability guideline of Chinese Pharmacopoeia 2010 editions two annex, investigate the placement medicine stability of 60 days under 25 DEG C 45 DEG C and relative humidity 75% condition.HPLC method is adopted to measure the content of pinoresinol diglucoside and chlorogenic acid in slow releasing preparation.
In addition, for embodying the superiority of granule of the present invention, ad hoc fixed following comparative example:
Comparative example 1: adjuvant is 150g chitosan, 150g cellulose acetate, 150g lactose, 100g mannitol and 2g magnesium stearate, and other are with embodiment 1;
Comparative example 2: adjuvant is 150g polyacrylic resin, 150g chitosan, 150g lactose, 100g mannitol and 2g magnesium stearate, other are with embodiment 1;
Comparative example 3: see embodiment 5 in patent documentation CN200610110223 description; In preparation, save other Chinese medicines only retain the Cortex Eucommiae.
Place under 45 DEG C and relative humidity 75% condition and respectively organize Effective Component of Chinese Medicine content (n=10) afterwards in 60 days
Embodiment 4
Release medium, for imitating human gastrointestinal tract environment (being 0.1mol/L hydrochloric acid before 2h, is the PBS buffer of pH6.8 after 2h), investigates the release of slow releasing tablet prepared by each embodiment respectively.
Release investigation method: the content first being measured puerarin, citric acid and Alisol B monoacetate in slow releasing tablet by HPLC, then release medium will be put into lot number slow releasing tablet and investigate release.
The release research in rat body of embodiment 5 slow releasing tablet
Get SD rat, after fasting 12h, gastric infusion (in Cortex Eucommiae extract 100mg/kg), gets blood in 1,4,8,12 and 24h eyeball respectively, and adopt HPLC-MS to measure each time point blood drug level, concrete outcome is see accompanying drawing 1.
Result as can be seen from accompanying drawing, not very stable in drug release process in slow releasing tablet prepared by comparative example 1 and 2, significantly prominent phenomenon of releasing is had to occur, and slow releasing tablet drug release rate prepared by embodiment 1 and 2 is comparatively steady, obvious pinoresinol diglucoside content still can be detected after 24 hours in blood.
Content of the present invention merely illustrates some claimed specific embodiments; one of them or more described technical characteristic can be combined with arbitrary one or more technical scheme in technical scheme; these technical schemes obtained through combination also in the application's protection domain, just as these technical schemes obtained through combination in the disclosure of invention concrete record.
Claims (4)
1. an eucommia bark depressor slow releasing preparation, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
Cortex Eucommiae extract 30 parts;
Polyacrylic resin 10 ~ 15 parts;
Chitosan 10 ~ 15 parts;
Cellulose acetate 5 ~ 10 parts;
Lactose 10 ~ 15 parts;
10 parts, mannitol;
Magnesium stearate 2 parts.
2. slow releasing preparation according to claim 1, is characterized in that, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
Cortex Eucommiae extract 30 parts;
Polyacrylic resin 15 parts;
Chitosan 10 parts;
Cellulose acetate 5 parts;
Lactose 15 parts;
10 parts, mannitol;
Magnesium stearate 2 parts.
3. slow releasing preparation according to claim 1, is characterized in that, the weight portion of described eucommia bark depressor slow releasing preparation consists of:
Cortex Eucommiae extract 30 parts;
Polyacrylic resin 10 parts;
Chitosan 15 parts;
Cellulose acetate 10 parts;
Lactose 10 parts;
10 parts, mannitol;
Magnesium stearate 2 parts.
4. prepare a method for the eucommia bark depressor slow releasing preparation described in any one of claim 1-3, concrete steps are as follows:
(1) Cortex Eucommiae extract, polyacrylic resin, chitosan, cellulose acetate, lactose and mannitol are uniformly mixed 15 minutes in high-speed mixer, obtain uniformed powder;
(2) in powder body, add appropriate 30% ethanol to granulate, vacuum drying makes water content lower than 5%, crosses 16 mesh sieves, and add magnesium stearate mixing, method tabletting, to obtain final product routinely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410706676.2A CN104490982B (en) | 2014-11-28 | 2014-11-28 | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410706676.2A CN104490982B (en) | 2014-11-28 | 2014-11-28 | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104490982A CN104490982A (en) | 2015-04-08 |
| CN104490982B true CN104490982B (en) | 2015-12-02 |
Family
ID=52932496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410706676.2A Active CN104490982B (en) | 2014-11-28 | 2014-11-28 | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490982B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579381B (en) * | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | Guanidine hydrochloride sustained release preparation and preparation method thereof |
-
2014
- 2014-11-28 CN CN201410706676.2A patent/CN104490982B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490982A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN101011381A (en) | Stomach floating tablet of bilobalide and preparation method thereof | |
| CN104490982B (en) | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof | |
| CN104224788A (en) | Medicinal composition of indapamide and folic acid and application of medicinal composition | |
| CN104306868A (en) | Medicine composition used for treating lung and kidney qi deficiency type chronic obstructive emphysema and preparation method thereof | |
| CN101757019B (en) | Medical composition for losing weight or treating metabolic syndromes | |
| CN103479763B (en) | Traditional Chinese medicine composition for treating borderline hypertension and preparation method thereof | |
| CN104435067B (en) | A kind of Cortex Eucommiae components composition and preparation thereof with myocardium protecting action | |
| CN103381209A (en) | Hawthorne leaf total-flavones sustained-release preparation and preparation method thereof | |
| CN101869567A (en) | Medicament composition containing biguanide antidiabetic medicament and sartan antihypertensive medicament and applications thereof | |
| CN102526470B (en) | Medicinal composition for treating primary hypertension | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| CN103272236B (en) | Medical composition and its use containing receptor,β blocker and vitamin B group | |
| CN103083367B (en) | Losartan ginkgo leaf compound preparation and preparation method thereof | |
| CN102058592B (en) | Azelnidipine and isosorbide dinitrate compound composition | |
| CN101214256A (en) | Syringopicroside tablet and preparation technique thereof | |
| CN107184760B (en) | Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof | |
| CN105477384A (en) | Traditional Chinese medicine composition capable of reducing blood pressure and preparation method of composition | |
| CN101869572A (en) | Composition containing biguanide antidiabetic medicament and ACEI (Angiotensin-Converting Enzyme Inhibitors) medicament and applications thereof | |
| CN110283061A (en) | New compound and its extracting method for blood pressure lowering | |
| CN104758289B (en) | A kind of compound antihypertensive drug combination and its application containing medetofazone | |
| CN101926792A (en) | Phospholipid complex containing silybin di-partial succinate, preparation method and application thereof | |
| CN103893368B (en) | The celestial clever Radix Rehmanniae compositions of Sugarless type and granule thereof and method for making | |
| CN103432122A (en) | Application of isocorynoxeine in preparation of antihypertensive drugs | |
| CN104069379B (en) | A kind of pharmaceutical composition and preparation method and purposes for treating hypertensive renal damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 343100 No. 5 Ji'an Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: Puzheng Pharmaceutical Group Co., Ltd. Address before: 343100 Puzheng Pharmaceutical Co., Ltd. Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee before: Puzheng Pharmaceutical Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200426 Address after: 343100 Innovation Avenue 278, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: Jiangxi Puzheng Pharmaceutical Co., Ltd. Address before: 343100 No. 5 Ji'an Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee before: PUZHENG PHARMACEUTICAL GROUP Co.,Ltd. |
|
| TR01 | Transfer of patent right |